Found: 4
Select item for more details and to access through your institution.
HIF-α Promotes Chronic Myelogenous Leukemia Cell Proliferation by Upregulating p21 Expression.
- Published in:
- Cell Biochemistry & Biophysics, 2015, v. 72, n. 1, p. 179, doi. 10.1007/s12013-014-0434-2
- By:
- Publication type:
- Article
Short-course bortezomib-based retreatment for patients with multiple myeloma who had received bortezomib-thalidomide-dexamethasone (VTD) as an initial therapy: A single-center case series.
- Published in:
- Experimental & Therapeutic Medicine, 2014, v. 7, n. 4, p. 977, doi. 10.3892/etm.2014.1496
- By:
- Publication type:
- Article
Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: A Chinese experience.
- Published in:
- American Journal of Hematology, 2010, v. 85, n. 7, p. 499, doi. 10.1002/ajh.21734
- By:
- Publication type:
- Article
CORRELATION BETWEEN THE EXPRESSION OF ARGININOSUCCINATE SYNTHETASE GENE AND DRUG RESISTANCE MECHANISM OF CHRONIC MYELOGENOUS LEUKAEMIA.
- Published in:
- Farmacia, 2017, v. 65, n. 2, p. 241
- By:
- Publication type:
- Article